The Johnson & Johnson (NYSE: JNJ) subsidiary Janssen has presented new long-term follow-up data at the 2023 American Society of Hematology (ASH) Annual Meeting from the Phase III GLOW and Phase II CAPTIVATE studies of first-line, fixed-duration treatment with Imbruvica (ibrutinib) plus AbbVie’s (NYSE: ABBV) Venclexta (venetoclax).
The GLOW study demonstrated an estimated 84.5% overall survival (OS) rate at 54 months, among older or comorbid patients with previously untreated chronic lymphocytic leukaemia (CLL) treated with the combination, compared to 63.7% for patients treated with chlorambucil plus obinutuzumab.
"Deep and durable responses, including in higher-risk patients"Phase II results from the CAPTIVATE study, which used a similar Imbruvica and Venclexta regimen to the GLOW study, showed deep remissions with clinical meaningful progression-free survival (PFS) with this combination.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze